DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A systematic review of metformin to limit weight-gain with atypical antipsychotics.

Author(s): Lee YJ, Jeong JH

Affiliation(s): Graduate School of Clinical Pharmacy, Sookmyung Women's University, Seoul, Korea. yujeunglee@yahoo.com

Publication date & source: 2011-10, J Clin Pharm Ther., 36(5):537-45. Epub 2011 Mar 21.

WHAT IS KNOWN AND OBJECTIVE: Weight-gain is commonly reported in patients taking atypical antipsychotic agents. A systematic review was performed to evaluate the effectiveness of metformin for attenuation of weight-gain induced by atypical antipsychotic agents. METHODS: A PubMed database (1966-May 2010) search was conducted, using metformin, atypical antipsychotic and weight-gain as search terms. Review articles, letters and commentaries were excluded. RESULTS AND DISCUSSION: Thirteen trials were identified (eight randomized, double-blind, placebo-controlled trials, one crossover adult trial, one open-label uncontrolled adult trial, two open-label uncontrolled paediatric trials and one case report). Of the eight randomized, double-blind, placebo-controlled trials, three studied adult subjects and one studied children. Metformin was well tolerated. The heterogeneity of the trials did not justify meta-analytic pooling of outcomes, and we provide a best evidence synthesis. WHAT IS NEW AND CONCLUSION: There is limited evidence for the efficacy of metformin in limiting weight-gain induced by atypical antipsychotic agents. However, the evidence is weak and further well-powered randomized, double-blind, placebo-controlled studies of longer duration should be conducted to confirm the preliminary evidence and provide better estimates of effect. (c) 2011 Blackwell Publishing Ltd.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017